Biomerica (BMRA) announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease, Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods Technology. These patents apply to countries under the European Patent Organization, including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO. These recent notices of allowance and issuance of patents are a significant milestone in Biomerica’s mission to enhance patient care through personalized medical solutions. The Company is currently marketing an inFoods Technology test to treat IBS sufferers, which is already covered by 15 different patents globally. The issuance of patents in these additional disease states opens the door for Biomerica to complete development of inFoods therapeutic products to treat patients within this broader spectrum of gastrointestinal diseases.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue